The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | First-in-human study of autologous memory-like NK cells in patients with MRD+ multiple myeloma
Giada Bianchi, MD, Brigham and Women’s Hospital & Dana-Farber Cancer Institute, Boston, MA, shares findings from a first-in-human trial exploring the safety and efficacy of autologous memory-like NK cells in patients with multiple myeloma undergoing autologous stem cell transplantation (autoSCT). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
